Across TCGA pan-cancer cohorts, EIF3JP1 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of EIF3JP1’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where EIF3JP1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types EIF3JP1 is over-expressed in tumor.

PRAD and LUSC are the cancer types where EIF3JP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EIF3JP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.034	.037	2	view →
LUSC	Male	All	+0.028	.040	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: EIF3JP1 RNA expression & survival · all EIF3JP1 data types